Quotables
"The Americans have need of the telephone, but we do not. We have plenty of messenger boys."
Sir William Preece, chief engineer, British Post Office ; 1878
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6171825 | Preparation of recombinant factor VIII in a protein free medium Recombinant Factor VIII can be produced in relatively large quantities on a continuous basis from mammalian cells in the absence of any animal-derived proteins such as albumin by culturing the cells in a protein free medium supplemented with polyol copoly... | 01/09/2001 |
| 5972632 | Anticomplement activity assays Immunoassays for complement components, complement activation products or, preferably both, can be used to determine an acceptable level of anticomplement activity (AC) in plasma derived biologically active products intended for infusion into a mammal. In... | 10/26/1999 |
| 5874408 | Stabilized albumin-free recombinant factor VII preparation having a low sugar content A stable albumin-free Recombinant Factor VIII (rFVIII) formulation in lyophilized form having both crystalline and amorphous components and comprising, when reconstituted with water, about 65 to 400 mM glycine, up to 50 mM histidine, 15 to 60 mM sucrose, ... | 02/23/1999 |
| 5763401 | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content A stable albumin-free Recombinant Factor VIII (rFVIII) formulation in lyophilized form having both crystalline and amorphous components and comprising, when reconstituted with water, about 65 to 400 mM glycine, up to 50 mM histidine, 15 to 60 mM sucrose, ... | 06/09/1998 |
| 5658746 | Cell surface receptor complementation A method of controlling the amount of a biologically active substance binding to a cell surface having both receptors to the substance and receptors for the Fc domain of an antibody that can complex with the substance or other antibodies that can complex ... | 08/19/1997 |
| 5654407 | Human anti-TNF antibodies Human monoclonal antibodies (mAbs) which bind to human TNF are disclosed. Autoantibodies of both the IgM and IgG isotypes are disclosed. A preferred human monoclonal antibody is known as B5 (F78-1A10-B5 mAb) and it binds to recombinant human TNF&#x... | 08/05/1997 |
| 5612033 | Methods of treatment using heat-treated IGM antibody preparations Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding... | 03/18/1997 |
| 5612213 | Method of selecting mammalian cell lines having improved productivity A method of selecting transfected cell lines for heterologous protein expression from a population of cells some of which include an endogenous sequence for an amplificable marker and some of which do not include the sequence. The method is based on a min... | 03/18/1997 |
| 5610285 | Purification of -1 proteinase inhibitor using novel chromatographic separation conditions Cation chromatography with solutions at pH less than 6.0 and low ionic strength can be utilized to purify human -1 proteinase inhibitor (-1 PI) from biological fluids including plasma and plasma fractions. The cation chromatography takes adv... | 03/11/1997 |
| 5561108 | Preparation of 1 -antichymotrypsin Human 댑 -antichymotrypsin (ACT) can be purified from solutions containing human 댑 -proteinase inhibitor (PI) and antithrombin III (AT-III) using chromatography adsorption steps at carefully controlled pH and conductivit... | 10/01/1996 |
| 5561115 | Low temperature albumin fractionation using sodium caprylate as a partitioning agent Highly stable plasma-derived therapeutic albumin solutions, having a turbidity level of 5 NTU or less can be made by adding sodium caprylate to Cohn fraction II+III or IV-1 effluent at relatively low temperatures. The sodium caprylate acts as a partitioni... | 10/01/1996 |
| 5527546 | Human interleukin 6 inhibitor A previously undescribed Interleukin-6 inhibitor activity has been successfully isolated from the supernatant of the human promyelocytic leukemia cell line HL-60. Treatment of the HL-60 cell line with cycloheximide prevents the appearance of the inhibitor... | 06/18/1996 |
| 5514781 | Use of azoles as virucidal agents in solutions of biologically active proteins Soluble azoles in aqueous solutions can be used as virucidal agents for biologically active protein preparations.... | 05/07/1996 |
| 5510465 | Heat-treated IgM antibody preparations Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding... | 04/23/1996 |
| 5419906 | Preparation of human immunoglobulin free of hepatitis C The effects of Cohn-Oncley cold alcohol fractionation on infectivity of two prototype retroviruses, mouse xenotropic type C and the LAV strain of AIDS retrovirus result in a significant reduction in retrovirus titer. At least a 100,000-fold reduction of L... | 05/30/1995 |
| 5330976 | Antimycotic compositions of nikkomycin compounds and azole antimycotics Nikkomycin compounds have been found to be orally or parenterally effective as anti-fungals in animals. They may be used alone or, preferably, in combination with azole antimycotics for a synergistic anti-fungal effect.... | 07/19/1994 |
| 5256771 | Heat treatment of IgM-containing immunoglobulins to eliminate non-specific complement activation Mild heat-treatment of IgM antibody concentrates diminishes the potential to induce non-specific complement activation without significant loss of normal immunologic effector functions. These IgM immunoglobulin concentrates retain specific antigen binding... | 10/26/1993 |
| 5194427 | Antimycotic compositions of nikkomycin compounds and azole antimycotics Nikkomycin compounds have been found to be orally or parenterally effective as anti-fungals in animals. They may be used alone or, preferably, in combination with azole antimycotics for a synergistic anti-fungal effect.... | 03/16/1993 |
| 5159064 | Preparation of virus-free antibodies Antibodies, including monoclonal antibodies (Mabs), can be made substantially free of infectious viruses by storing them in a liquid state at conditions of pH, temperature and time sufficient to inactive substantially all infectious viruses. Preferred ina... | 10/27/1992 |
| 5149795 | Nikkomycin derivatives The nikkomycin compound possessing antimycotic activity and having the following structure: ##STR1##... | 09/22/1992 |
| 5134126 | Antimycotic compositions of nikkomycin compounds and azole antimycotics Nikkomycin compounds have been found to be orally or parenterally effective as anti-fungals in animals. They may be used alone or, preferably, in combination with azole antimycotics for a synergistic anti-fungal effect.... | 07/28/1992 |
| 5115101 | Removal of protein A from antibody preparations Antibody preparation purified using immobilized protein A and yet substantially free of protein A that may have solubilized during the purificaiton process. The antibodies include less than 15 ng protein A per mg of antibody, preferably less than 1 ng/mg.... | 05/19/1992 |
| 5110910 | Virucidal euglobulin precipitation A source for antibodies (both IgG and IgM types) is put into an aqueous solution which includes a virucidal agent under conditions sufficient to assure substantially complete dissolution of both the antibodies and the virucidal agent and virus inactivatio... | 05/05/1992 |
| 5096889 | Antimycotic compositions of nikkomycin compounds and azole antimycotics Nikkomycin compounds have been found to be orally or parenterally effective as anti-fungals in animals. They may be used alone or, preferably, in combination with azole antimycotics for a synergistic anti-fungal effect.... | 03/17/1992 |
| 5091375 | Nikkomycin derivatives Nikkomycin derivatives have been found to be orally or parenterally effective as anti-fungals in animals. They may be used alone or, preferably, in combination with azole antimycotics for a synergistic anti-fungal effect.... | 02/25/1992 |
| 5089146 | Pre-storage filtration of platelets Filtration of white blood cells (WBCs) directly from platelet rich plasma (PRP) rather than from subsequently made platelet concentrates (PC). Earlier filtration is effective at removing most WBCs with minimal platelet loss and permits storage of platelet... | 02/18/1992 |
| 5071650 | Use of intermediate length alcohols as virucidal agents in solutions of biologically active proteins Soluble, intermediate length alcohols (C4 -C10) in aqueous solutions at low pH (4.0-7.0) can be used as virucidal agents for therapeutic biologically active protein preparations. Treatment with the alcohols is especially useful for p... | 12/10/1991 |
| 5030619 | Synergistic fungicidal composition A fungicidal composition comprising a nikkomycin and an echinocandin B. Method of treating a fungal infection comprising administering therapeutically effective amounts of a combination of the nikkomycin and the echinocandin B. Composition and method are ... | 07/09/1991 |
| 5019560 | Method for treating fungal infections with nikkomycin derivatives A method of treating a mammal infected with a dimorphic, highly chitinous fungi, the method comprising administering to the mammal therapeutically effective amounts of a nikkomycin derivative having the following structure: ##STR1##... | 05/28/1991 |
| 5006472 | Enzymatic purification process Controlled enzymatic treatment may be used to selectively degrade undesirable contaminants to a size or charge range which can be more readily removed by subsequent separation steps. Treatment is especially useful for purifying rDNA or monoclonal antibody... | 04/09/1991 |
| 5006513 | Antimycotic compositions of nikkomycin compounds and azole antimycotica Nikkomycin compounds have been found to be orally or parenterally effective as anti-fungals in animals. They may be used alone or, preferably, in combination with azole antimycotics for a snyergistic anti-fungal effect.... | 04/09/1991 |
| 4994269 | Topical use of antibodies for prevention or treatment of pseudomonas infections Method of preventing or treating a Pseudomonas aeruginosa infection. Method comprises topical application of antibodies to P. aeruginos under conditions and in an amount sufficient to prevent or treat the infection in a mammal. In one embodiment, the anti... | 02/19/1991 |
| 4994057 | Sterilizable system for blood storage An improved heat sterilizable blood bag system adapted for containing and mixing of different materials originally placed in separate but potentially communicating compartments. The improvement comprises of having a smaller squeezable compartment for one ... | 02/19/1991 |
| 4975186 | Container for fine separation of blood and blood components Blood and blood component container having in continuous communication therewith a receptacle adapted to receive and define a given component or sub-component when contents in the container are separated. In preferred embodiments, the container is a flexi... | 12/04/1990 |
| 4969882 | Bag for separation and isolation of blood components A generally flat, elongated edge-sealed polymeric blood bag having a length to width ratio of at least 2 to 1 and one end portion in tapering communication with a connected tubing. When the bag is filled with a mixture of blood components which are then s... | 11/13/1990 |
| 4954251 | Concentric microaggregate blood filter Microaggregate blood filter adapted to pre-filter aggregates larger than 150 microns without interfering with the on-going and continuous filtration of aggregates between 40 and 150 microns. Filter comprises a flexible housing having inlet and outlet port... | 09/04/1990 |
| 4948877 | Preparation of retrovirus-free immunoglobulins Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by storing the ISG in a liquid state at conditions of pH, temperature and time sufficient to inactivate substantially all infectious retroviruses. Preferred inactivatio... | 08/14/1990 |
| 4943287 | Red blood cell storage system Closed blood bag system for long term storage of red blood cells (RBCs) without contamination due to storage. System comprises the combination of a white blood cell (WBC) filter in sterile communication with a plastic bag made from a film substantially fr... | 07/24/1990 |
| 4939176 | Viral inactivation process Lipid-enveloped viruses present in purified biologically active protein products obtained from blood or cell culture systems can be inactivated by contacting the products with caprylic acid at a non-ionized concentration, pH, temperature and ionic environ... | 07/03/1990 |
| 4921792 | Continuous cell dispersion, cultivation and substance recovery process A system for continuous production and removal of a biological substance from a dispersed cell culture. The system comprises a reactor adapted to maintain the cell culture under incubating conditions and means for pumping limited volumes of the culture fl... | 05/01/1990 |
